Stage 4 Prostate Cancer PSA Drop: Real Case Showing >99% Reduction After ECCT Integration

When this Malaysian, 39-year-old male was diagnosed in early October 2025, evaluation confirmed metastatic prostate adenocarcinoma with both nodal and extensive skeletal involvement. CT imaging demonstrated left iliac and para-aortic lymphadenopathy together with diffuse sclerotic and lytic bone lesions involving the pelvis and spine. PET-CT performed on 14 October 2025 confirmed PSMA-avid disease within the prostate, nodal metastases, and widespread skeletal involvement. Histopathology showed acinar adenocarcinoma with Gleason score 4+4 (Grade Group 4), consistent with high-risk disease biology.

At diagnosis, hix PSA was markedly elevated at 784 (October 2025), indicating a substantial systemic tumor burden. Systemic treatment was initiated with chemotherapy in combination with androgen deprivation (pamorelin) and androgen receptor pathway inhibition (enzalutamide). ECCT was incorporated into his treatment plan on 11 December 2025 as a non-invasive adjunct and continued alongside ongoing oncologic therapy.

Following this integration, PSA demonstrated a sustained and progressive decline, reaching 6.96 (6 January 2026), 4.87 (27 January 2026), 3.19 (24 February 2026), and ultimately 3.01 (24 March 2026). This represents a reduction of PSA Drop greater than 99% from baseline, with a consistent downward trajectory and no interval rise. In metastatic prostate cancer, sustained suppression of PSA over time is clinically significant and reflects continued control of tumor activity.

In parallel, hematologic parameters demonstrated recovery rather than treatment-related decline. Hemoglobin improved from 7.7 (4 November 2025) to 12.9 (24 March 2026), reflecting resolution of initial anemia. Platelet counts remained within acceptable ranges, and there was no evidence of clinically significant bone marrow suppression despite ongoing chemotherapy. White blood cell profiles remained stable without recurrent infection, suggesting preserved immune function during treatment. Biochemical trends further demonstrated maintenance of organ function.

Initial elevations in liver enzymes (ALP 386, ALT 116, AST 57 on 4 November 2025) showed progressive improvement over time, with ALP decreasing to 123, ALT to 15, and AST to 16 by March 2026. Renal function remained stable across serial measurements, with creatinine values consistently in the mid-50s and eGFR maintained above 120, indicating preserved renal function. Electrolytes remained within normal limits throughout.

Key Clinical Interpretation for PSA Drop

• Tumor Activity: PSA reduced by more than 99%, showing sustained biochemical response

• Hematologic Recovery: Hemoglobin normalized from anemia without marrow suppression

• Liver Function: Significant improvement with normalization of ALT and AST

• Renal Function: Remained stable and within normal limits

• Overall: No evidence of treatment-limiting toxicity; systemic function preserved

  
  

Clinically, the patient maintained stable performance status without development of significant systemic symptoms. There was no progression to bone pain, functional decline, or treatment-limiting toxicity during this period. He continues systemic therapy with ongoing monitoring. While follow-up imaging has not yet been performed, the magnitude and consistency of PSA reduction, together with recovery of hematologic parameters and preservation of organ function, support sustained disease control at a biological level.

This case demonstrates that in metastatic prostate adenocarcinoma, meaningful treatment response can be reflected through sustained biochemical suppression alongside preserved systemic function. A >99% reduction in PSA, combined with normalization of hematologic and biochemical parameters, represents a clear shift toward biological control under active treatment. This is presented not as a claim of cure, but as objective documentation of response and maintained physiological stability within a structured, closely monitored therapeutic approach.